Guest Editors
Dr. Abdul Hamid Bazarbachi
Email: bazarbachi@gmail.com
Affiliation: Division of Hematology/Oncology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USA
Homepage:
Research Interests: hematology, oncology, multiple myeloma, acute leukemia
Summary
Multiple myeloma (MM) is a malignant plasma cell disorder characterized by clonal proliferation in the bone marrow, immune dysfunction, and a highly heterogeneous genetic landscape. Although significant progress has been made over the past two decades with the introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplantation, MM remains largely incurable due to eventual relapse and drug resistance. The treatment paradigm is now rapidly evolving with the emergence of novel immunotherapies such as CAR-T cells, bispecific T-cell engagers, antibody-drug conjugates, and small-molecule inhibitors targeting specific oncogenic pathways.
This Special Issue aims to present original research and critical reviews focusing on the latest therapeutic strategies for MM, including preclinical studies on molecular targets, translational research bridging bench to bedside, and clinical data on novel drug combinations or sequencing strategies. We particularly encourage submissions addressing mechanisms of drug resistance, identification of predictive and prognostic biomarkers, tumor microenvironment interactions, and personalized approaches to MM therapy. By gathering contributions from leading experts in hematology, oncology, and translational medicine, this Special Issue seeks to promote innovative solutions and accelerate progress toward more effective and durable treatments for multiple myeloma.
Keywords
Multiple myeloma, Targeted therapy, Immunotherapy, Drug resistance, CAR-T cells, Tumor microenvironment, Biomarkers, Precision oncology
Login
Register
Submit a Paper
Propose a Special lssue